RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$791M
AUM Growth
+$791M
(-9.1%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-9.51%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
$15.7M |
| 2 |
Eli Lilly
LLY
|
$12.6M |
| 3 |
Encompass Health
EHC
|
$12.1M |
| 4 |
Cardinal Health
CAH
|
$9.24M |
| 5 |
Neurocrine Biosciences
NBIX
|
$7.47M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 2 |
Oscar Health
OSCR
|
$15.2M |
| 3 |
Procept Biorobotics
PRCT
|
$14.9M |
| 4 |
UnitedHealth
UNH
|
$14.7M |
| 5 |
McKesson
MCK
|
$14.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Apellis Pharmaceuticals
APLS
$3.48B
| $1.61M | 0.2% |
93,250
+65,000
| +230% | +$1.13M |
|
77
Relay Therapeutics
RLAY
$619M
| $1.59M | 0.2% |
460,000
| – | – |
|
78
Biogen
BIIB
$19.4B
| $1.51M | 0.19% |
12,000
-37,500
| -76% | -$4.71M |
|
79
Kura Oncology
KURA
$686M
| $1.44M | 0.18% |
250,000
+55,000
| +28% | +$317K |
|
80
Denali Therapeutics
DNLI
$2.23B
| $1.4M | 0.18% |
100,000
| – | – |
|
81
Xencor
XNCR
$580M
| $1.3M | 0.16% |
165,750
-30,000
| -15% | -$236K |
|
82
Doximity
DOCS
$12.7B
| $1.29M | 0.16% |
+21,000
| New | +$1.29M |
|
83
Janux Therapeutics
JANX
$1.37B
| $1.27M | 0.16% |
55,127
-86,500
| -61% | -$2M |
|
84
Alkermes
ALKS
$4.78B
| $1.12M | 0.14% |
39,000
| – | – |
|
85
Iovance Biotherapeutics
IOVA
$807M
| $1.11M | 0.14% |
647,827
| – | – |
|
86
Annexon
ANNX
$226M
| $1.1M | 0.14% |
460,000
| – | – |
|
87
Xenon Pharmaceuticals
XENE
$2.98B
| $1.1M | 0.14% |
35,000
| – | – |
|
88
Immunocore
IMCR
$1.62B
| $887K | 0.11% |
28,278
| – | – |
|
89
Bio-Techne
TECH
$8.5B
| $772K | 0.1% |
+15,000
| New | +$772K |
|
90
INmune Bio
INMB
$54M
| $412K | 0.05% |
178,284
| – | – |
|
91
Amgen
AMGN
$155B
| – | – |
-4,000
| Closed | -$1.25M |
|
92
Arvinas
ARVN
$568M
| – | – |
-183,000
| Closed | -$1.28M |
|
93
Avantor
AVTR
$9.18B
| – | – |
-47,826
| Closed | -$775K |
|
94
Becton Dickinson
BDX
$55.3B
| – | – |
-19,000
| Closed | -$4.35M |
|
|
95
Bristol-Myers Squibb
BMY
$96B
| – | – |
-325,000
| Closed | -$19.8M |
|
96
Esperion Therapeutics
ESPR
$448M
| – | – |
-1,066,495
| Closed | -$1.54M |
|
97
Geron
GERN
$893M
| – | – |
-783,000
| Closed | -$1.24M |
|
98
Humana
HUM
$36.5B
| – | – |
-46,830
| Closed | -$12.4M |
|
99
Icon
ICLR
$13.8B
| – | – |
-7,000
| Closed | -$1.22M |
|
100
IDEAYA Biosciences
IDYA
$2.15B
| – | – |
-39,500
| Closed | -$647K |
|